IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

HIRSCH ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/003513

FILED: 2 APRIL 2004

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: PHARMACEUTICAL COMPOSITION COMRPSING AN

IMMUNOSUPPRESSANT FOR USE IN THE TREATMENT OF SKIN

DISEASES

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2004/003513, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-2614

Date: 9/22/25

Gregory W Houghton , Attorney for Applicants

Reg. No. 47,666

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PD/4-32804A
APPLICATION NO. Not Yet Known
APPLICANT
HIRSCH ET AL.
FILING DATE
Herewith

Group

JC14 Rec'd PCT/PTO 23 SEP 2005

| | | | U.S. | PATENT DOCUMENTS | | | | |
|---------------------|----|---|----------------------------|---|----------------------------|--------------------------------|-------------|---------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILI | NG DATE |
| - | AA | 2002/044967 | 4/18/02 | Ibuki et al. | | | | |
| | AB | | | | | | | |
| J | AC | | | | | | | |
| | AD | | | | | | | |
| | AE | | | | | | | |
| | AF | | | | | | | |
| | AG | | | | | | | |
| | АН | | | | | | | |
| | Al | | - | | | | | |
| | AJ | | | | | | | |
| | AK | | | | | | | |
| | AL | | | | | | | |
| | | | FOREIG | ON PATENT DOCUMENTS | | | | |
| | | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRAN YES | SLATION NO |
| | АМ | 0 812 588 | 12/17/97 | EP | | | | |
| | AN | 1 064 942 | 1/3/01 | EP | | | | |
| | AO | 1 273 288 | 1/8/03 | EP | | | | |
| | AP | 2 327 610 | 2/3/99 | GB | | | | |
| | AQ | 96/13249 | 5/9/96 | wo | | | | |
| | | | | (Including Author, Title, Date, Pertin | | | | |
| | AR | Kapp et al., "Long-Te Drug", Journal of Alle | rm Manager rgy and Clin | ment of Atopic Dermatitis in Infa ical Immunology, Vol. 110, No. | ants with To 2, pp. 277 | opical Anti-In -284 (2002). | flamma | atory |
| | AS | | | | | | | |
| | АТ | | | | | | | |
| EXAMIN | FR | | | DATE CONSIDERED | | | | |

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. DEPARTMENT OF COMMERCE

ATTY. DOCKET NO. PD/4-32804A
APPLICATION NO. Not Yet Known **APPLICANT** HIRSCH ET AL. **FILING DATE** Herewith

Sheet 2 of 2 10/550357

Group

FOREIGN PATENT DOCUMENTS

| CA CB CC CD CE CF | 97/25977 00/32234 03/074054 2004/016289 | 7/24/97 6/8/00 9/12/03 2/26/04 | wo wo | | | YES | NO |
|-----------------------|--|---|-----------------|---|---|-----|----|
| CC CD CE | 03/074054 | 9/12/03 | wo . | | | | |
| CD CE | | | · | | | | ╽Ш |
| CE | 2004/016289 | 2/26/04 | · | I | | | |
| | | | wo | | | | |
| CF | | | | ¥ | , | | |
| ۱ ۵۰ | | | | | | | |
| CG | | | | | , | | |
| СН | | | | | | | |
| CI | | | | | | | |
| CJ | | | | | | | |
| СК | | | | | | | |
| CL | | | | | | | |
| СМ | | | | | | | |
| CN | | | | | | | |
| СО | | | | | | | |
| СР | | | | | | | |
| CQ | | | | | | | |
| CR | | | | | | | |
| cs | | | | | | | |
| СТ | - | | | | | | |
| CU | | | | | | | |
| CV | | | | | | | |
| CW | | | 1 | | | | |
| СХ | | | | | | | |
| CY | | | | | | | |
| CZ EXAMINER | | | DATE CONSIDERED | | | | |

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.